CRISPR editing of miR-33 restores ApoE lipidation and amyloid-β metabolism in ApoE4 sporadic Alzheimer’s disease
Brain · 2025
DOI: 10.1093/brain/awaf244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Boyoung Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Genetics, College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea. Hauptthemen laut MEDLINE: MicroRNAs, Alzheimer Disease, Gene Editing, Apolipoprotein E4. Die Arbeit nennt 68 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korean government, Bio & Medical Technology Development Program.
Themen: Demenz
Abstract (Originalsprache)
Sporadic Alzheimer’s disease (sAD) is marked by dysregulated lipid metabolism, prominently involving apolipoprotein E (ApoE). MicroRNA-33 (miR-33) has emerged as a key regulator of lipid homeostasis, yet its role in sAD remains unclear. This study investigated miR-33 dysregulation in APOE ε4 allele (ApoE4)-associated sAD and explored its therapeutic potential using clustered regulatory interspaced short palindromic repeats (CRISPR)-mediated gene editing. Elevated miR-33 expression was observed in both AD patients, particularly those with ApoE4-associated sAD, and in the ApoE4 mouse model, implicating its role in AD pathology. Using CRISPR/Cas9, we modulated miR-33 expression in astrocytes to regulate ApoE lipidation and ameliorate AD-related pathology. Our results show that targeted miR-33 regulation in astrocytes via CRISPR/Cas9 restores ApoE lipidation and mitigates AD pathology in both in vitro and in vivo AD mice. Additionally, applying this gene therapy approach in ApoE4 sAD patient cell lines highlights its translational potential for therapeutic intervention. In conclusion, our findings elucidate miR-33’s role in AD pathogenesis and underscore the therapeutic promise of CRISPR-mediated miR-33 targeting for restoring lipid homeostasis and ameliorating AD pathology. This study provides valuable insights into developing miRNA-based gene therapy strategies for treating sAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Genetics, College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
- College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
- College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
ORCID-Profile: Hanseul Park
Förderung
- National Research Foundation of Korea
- Korean government
- Bio & Medical Technology Development Program
- National Research Foundation
Zitieren
APA
Kim, B., Yuk, M., Park, M., Ryu, H., Park, J., Yu, H., Park, S., Hong, J. T., Lim, K. H., Han, S. B., Song, N., & Park, H. (2025). CRISPR editing of miR-33 restores ApoE lipidation and amyloid-β metabolism in ApoE4 sporadic Alzheimer’s disease. Brain. https://doi.org/10.1093/brain/awaf244
Vancouver
Kim B, Yuk M, Park M, Ryu H, Park J, Yu H, et al. CRISPR editing of miR-33 restores ApoE lipidation and amyloid-β metabolism in ApoE4 sporadic Alzheimer’s disease. Brain. 2025. doi:10.1093/brain/awaf244
BibTeX
@article{Kim2025,
author = {Kim, Boyoung and Yuk, Minju and Park, Moonsu and Ryu, Hongji and Park, Junhang and Yu, Hyerin and Park, Sungsoo and Hong, Jin Tae and Lim, Key-Hwan and Han, Sang-Bae and Song, Nan and Park, Hanseul},
title = {CRISPR editing of miR-33 restores ApoE lipidation and amyloid-β metabolism in ApoE4 sporadic Alzheimer’s disease},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awaf244}
}
EUVIMED